KEISHA YAHAGI: Open Payments
NPI 1073953394 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,671 in 120 payments from 12 companies in 2025. Trend: 2023 $1,148 · 2024 $1,756 · 2025 $1,671
Food & beverage: $1,671
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 13 | $305 |
| E.R. Squibb & Sons, L.L.C. | 36 | $273 |
| Alkermes, Inc. | 14 | $224 |
| Neurocrine BioSciences, Inc. | 6 | $177 |
| ABBVIE INC. | 14 | $171 |
| Teva Pharmaceuticals USA, Inc. | 11 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $141 |
| Otsuka America Pharmaceutical, Inc. | 12 | $138 |
| Lundbeck LLC | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
Products named: INVEGA SUSTENNA, COBENFY, ARISTADA, INGREZZA, VRAYLAR, UZEDY, CAPLYTA, REXULTI.
Industry payments across TX — which companies pay providers there.
